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Infection of Hepatitis B virus (HBV) in hepatocytes has been known to be controlled by multiple cellular
factors, while the relationship of the infection and liver microRNAs remains obscure. In this study,
a miRNA database, containing 168 unique mature miRNA members from primary hepatocytes of a
primate-like animal, northern treeshrew (Tupaia belangeri) that is the only species susceptible for HBV
infection other than human and chimpanzee, was established. The relative level of a liver predominant
microRNA, miR-122, was markedly increased upon HBV infection of the primary tupaia hepatocyte (PTH).
However, introducing neither miR-122 nor its antagonist anti-miR-122 into PTHs, or, HepG2–NTCP that is
HepG2 cells with the newly identiﬁed receptor sodium taurocholate cotransporting polypeptide (NTCP)
did not alter the viral infection on these cells. These data suggest that de novo HBV infection of cultured
hepatocytes does not depend on the expression level of intracellular miR-122 of the target cells.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Hepatitis B Virus (HBV) is a small DNA virus replicating via a
unique reverse transcription step that is accurately regulated by
viral and host factors (Dandri and Locarnini, 2012; Hirschman,
1979; Seeger and Mason, 2000). It infects liver parenchyma
hepatocytes and causes acute or chronic hepatitis. About 2 billion
people have been infected by HBV and 240 million of them are
chronically infected worldwide. HBV infection frequently leads to
more sever diseases such as cirrhosis and liver cancer and about
600,000 people die of HBV and its associated diseases annually
(Ott et al., 2012; Wright, 1980). Available treatments for HBV,
including interferon and nucleotide/nucleoside analogs, may
reduce viral load but hardly lead to a cure for hepatitis B (Lai
and Yuen, 2008). Novel interventions targeting to other steps of
the viral life cycle with new action mechanisms are needed.
MicroRNAs (miRNAs) are small non-coding RNA molecules
found in plants and animals. Biogenesis of miRNA is from a long
primary transcripts, it functions in transcriptional and post-
transcriptional regulation levels by targeting a diverse set of
cellular genes (Murchison and Hannon, 2004). There are increas-
ing evidences indicating that miRNAs also play important roles in
virus infection. It has been shown that miR-122 is critical for
hepatitis C virus (HCV) infection (Jopling et al., 2005). By interact-
ing with the 5′ non-coding region of the HCV genome, miR-122
greatly facilitates HCV viral RNA replication; while sequestration of
miR-122 in the liver resulted in marked loss of HCV viral RNAs
in vitro and in vivo (Jopling et al., 2005). Recently, inhibiting miR-
122 was shown to be an effective strategy in treating HCV infected
primates or patients with high efﬁcacy, prolonged virological
response and low risk of resistance (Lanford et al., 2010; Janssen
et al., 2013). Modulating miRNA thus presents a new and promis-
ing strategy for treatment against viral infections.
Studies of the infection of HBV, including those on the inter-
plays of the virus and cellular miRNAs, has been impeded by the
lack of an effective culture system in vitro. Indeed, only primary
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human hepatocyte (PHH), primary Tupaia belangeri hepatocyte
(PTH) and HepaRG, a human hepatic progenitor cell line, were
shown to be able to support viral infection of HBV in vitro (Glebe
and Urban, 2007). Therefore, previous investigations regarding
miRNA for HBV infection were mainly carried out by using
transfection of viral DNA into hepatocarcinoma cell line HepG2
or Huh7 (Liu et al., 2011; Wang et al., 2012). Among various
miRNAs, miR-122 was of particular interest to HBV infection due to
its high liver speciﬁcity and abundance as well as its important
role in liver homeostasis (Chen et al., 2011; Li et al., 2013; Tsai
et al., 2012). However, the physiological relevance of these studies
remains uncertain since they were not from bona fade HBV
infection. Using the primary hepatocytes from tupaia, we recently
showed that sodium taurocholate cotransporting polypeptide
(NTCP), a liver bile acids transporter responsible for most Naþ-
dependent bile acids uptake in hepatocytes, is a functional
receptor for HBV, its satellite Hepatitis D virus (HDV) (Yan et al.,
2012) and infection of woolly monkey HBV (WMHBV) on PTH
(Zhong et al., 2013). HepG2 cells complemented with human or
tupaia-NTCP could be infected by HBV at a similar efﬁciency of
that on primary human hepatocytes. In this study, we proﬁled the
expression of microRNAs in PTH through RNA deep sequencing,
we further utilized PTH as well as HepG2–NTCP culture systems to
investigate the role of miRNA-122 in the de novo HBV infection of
the target cells.
Results
RNA deep sequencing of the small RNAs from hepatocytes of
treeshrew and establishment of tupaia hepatocyte microRNA
databases
We ﬁrst generated a tupaia hepatocyte miRNA database by
using whole RNA from PTH from tree shrew (Tupaia belangeri
chinensis). Freshly isolated PTH were cultured on collagen coated
plates and inoculated or not with HBV at 100 multiplicities of
genome equivalents (m.g.e.). Total RNA was extracted on 5 days
post inoculation (5 dpi), RNA with size between 18–28 nt was
fractionated by 7 M urea denaturing PAGE Gel. These small RNAs
were ligated with the adapters at both 3′ end and 5′ end, followed
by reverse transcription and polymerase chain reaction (RT–PCR)
to amplify the cDNA, the small DNA was then sequenced with the
method of 36 cycle single end sequencing using a Genome
Analyzer IIx instrument (Fig. 1A). After data collection and proces-
sing, about 10 million raw total reads of miRNA were obtained in
Fig. 1. Proﬁling miRNAs of treeshrew hepatocyte by deep sequencing: (A) Flow chart of miRNA data collection and processing. Fresh PTHs were isolated and plated, the cells
were inoculated or not with HBV. At 5 dpi, total RNA were extracted, small RNAs with size of 18–28 nt were fractioned from 5–10 μg of total RNA using 7 M urea
polyacrylamide gel. cDNA libraries was prepared by RT–PCR after adapter ligation at 3′ and 5′. The cDNAs were sequenced with a 36 cycle single end sequencing protocol on
a Genome Analyzer IIx, Illumina instrument. Total raw reads were obtained, and subjected to data analysis, unique mature miRNA was presented. (B) Pie chart of microRNA
raw reads of uninfected PTH. Total reads were 10,903,960. Low quality reads and adapter sequences were discarded (0.47%). After prediction by miRDeep2, about 26.85%
of small RNA was ﬁltered. The precursors and mature sequences passed ﬁltering were further selected, and additional 5.47% of total raw reads was discarded. About 67.22%
of total raw reads passed the entire ﬁltering and selection process. (C) The number of precursors and unique mature miRNAs from PTH. 179 precursors and 168 unique
mature miRNAs was obtained.
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mock and HBV infection samples respectively. These raw data
were then ﬁltered by trimming adapter sequence and removing
reads shorter than 18 nt, the majority of reads passed ﬁltering,
indicating high quality of the sequencing. Based on the newly
completed genome sequence of treeshrew (Fan et al., 2013),
miRNAs were predicted by software miRDeep2 and ﬁltered by
miRDeep2 score, reads number and other criteria as described in
the “Materials and Method” Section. Fig. 1B showed the statistics
of microRNA sequencing data from tupaia primary hepatocytes.
Total 179 precursors and 168 unique mature miRNAs were
successfully identiﬁed (Fig. 1C). The vast majority of these miRNAs
(147 miRNAs) can be annotated to corresponding human miRNAs,
while 27 miRNAs are novel ones, among which 15 have orthologs
in other species (Supplemental Table 1). Of note, we did not ﬁnd
any miRNA reads corresponding to the genome of HBV, conﬁrming
that, unlike some DNA viruses such as Epstein–Barr virus (EBV)
(Pfeffer et al., 2004), HBV does not encode any miRNAs (Liu
et al., 2011).
The level of miR-122 was increased upon HBV infection of target cells
in culture
We next compared the expressing proﬁles of miRNAs of PTH
in the presence or absence of HBV infection to identify possi-
ble miRNAs that may be involved in HBV infection process
(Supplemental Table 2). The copy numbers of all the mature
miRNAs from HBV infected or mock infected sample were plotted,
the abundance of most of the miRNAs did not alter, irrespective
of the infection (Fig. 2A). Among those changed, microRNAs with
reads count over 10 Read Per Million (RPM) in the uninfected
sample was selected for further analysis. Copies of 14 miRNAs
were increased over 1.5-fold and copy numbers of 11 miRNAs
showed over 40% reduction upon HBV infection (Supplemental
Table 3). The copy number of miR-122 was increased from 83300.9
RPM to 143765.9 RPM, showing a 1.72-fold increase upon HBV
infection. miR-122 is a miRNA predominantly expressed in liver
and plays pivotal roles in the liver homeostasis and hepatocarci-
nogenesis (Chang et al., 2004; Coulouarn et al., 2009; Lagos-
Quintana et al., 2002). Sequencing of tupaia miRNA precursor
mir-122 (Supplemental Fig. 1) revealed that treeshrew mir-122
is conserved comparing to that of other species and presumably
exhibits a standard stem-loop secondary structure (Fig. 2B). We
also conducted quantitative real-time PCR following reverse tran-
scription (RT–qPCR) to examine the levels of intracellular miR-122
at different time points. Comparing to the mock-infected cells, the
relative miR-122 level in HBV infected PTH was increased from day
4 to day 8 post infection (Fig. 2C). Interestingly, in agreement
with this result from HBV infected primary tupaia hepatocytes
in vitro, the level of miR-122 is signiﬁcantly higher in the sera
of HBV patients comparing to that of the healthy individuals
Fig. 2. Increased level of miR-122 in primary tupaia hepatocytes infected by HBV: (A) Comparison of expression level of miRNAs in HBV infected, or mock infected PTH. The X
and Y-axis showed Reads Per Million (RPM) of mature miRNAs. The arrow refers to Tupaia miR-122, which is identical to has-miR-122. (B) Predicted secondary structure of
treeshrew miR-122 precursor by miRDeep2. Mature sequence is shown in bold, star sequence is shown in gray, and loop is in light gray. (C) RT–qPCR detection of the relative
miR-122 level at dpi 2, 4, 6 and 8 of HBV infected PTH, copies of U6 were used as internal control (left). HBV infection was examined with HBeAg ELISA (right). (D) The level of
miR-122 in the sera of HBV infected patients, comparing to that from healthy individuals (po0.05). The relative level was calculated by using cel-miR-238 spiked in the
samples as an inner control in the RT–qPCR (Mitchell et al., 2008).
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(Fig. 2D). Some recent studies have also showed that miR-122
level is increased in HBV positive patients (Arataki et al., 2013;
Waidmann et al., 2012).
Introducing mimic or inhibitor of miR-122 did not interfere with HBV
infection on PTH
In order to elucidate the functionality of miR-122 in HBV
infection, we further conducted series HBV infection experiments
using HBV susceptible cells. We ﬁrst constructed luciferase repor-
ter systems to examine the efﬁcacy of the miR-122 mimic in target
cells. The coding sequence of ﬁreﬂy luciferase gene was fused to
a 3′ untranslated region (UTR) sequence containing three miR-122
targeting sites that was originated from SLC7A1 mRNA
(Bhattacharyya et al., 2006; Johnson et al., 2005). The miRNA
ﬁreﬂy luciferase reporter plasmid was contransfected with an
internal control plasmid expressing renilla Luciferase. The ﬁreﬂy
and renilla luciferase activity in the target cells was determined
after transfection of 50 nM synthesized miR-122, anti-miR-122 or
controls. miR-122 markedly inhibited the expression of ﬁreﬂy
luciferase from the reporter bearing the miR-122 binding sites at
its 3′ UTR, but not the control reporter without miR-122 binding
site (Fig. 3A). We then examined if de novo HBV infection on
primary tupaia hepatocytes could be modulated by miR-122 by
introducing mimic or inhibitor of miR-122. Freshly isolated PTHs
were transfected with miR-122 or anti-miR-122 in 48-well plates
for 5 h with PTH attachment medium, and the cells were then
cultured in PTH maintenance medium (Glebe et al., 2003), and
were challenged with HBV at 100 m.g.e. 48 h later. miR-cy3 and
anti-miR-cy3 with scramble miRNA sequence were used as con-
trols. Secreted HBV viral e antigen (HBeAg) in the supernatant was
examined with commercial ELISA kits at different days post
infection. No signiﬁcant difference was found between the control
groups treated with miR-cy3 and the cultures treated with miR-
122. Transfecting cells with miR-122 inhibitor, anti-miR-122 or a
control inhibitor anti-miR-cy3, did not alter the HBV infection
either. Additional control microRNA mimics and inhibitors includ-
ing miR-let-7c, anti-miR-let-7c and miR-NC (Shanghai Gene
Pharma, China) was also tested to evaluate the effect of miR-122
for HBV infection under the same condition (Fig. 3B). The data
again showed that, comparing to all the controls, neither miR-122
nor anti-miR-122 was able to modulate HBV infection. These result
indicated that miR-122 level per se might not be critical for HBV
infection in primary tupaia hepatocytes.
HBV infection did not depend on the level of intracellular miR-122 on
HepG2 cells complemented with NTCP
HepG2–hNTCP is a HepG2 cell line complemented with human
NTCP, which can be infected by HBV, HDV and WMHBV (Yan et al.,
2012; Zhong et al., 2013). We examined the levels of miR-122
expression in this cell line, its parental cell HepG2, a HepG2
derivative cell line HepG2.2.15 that harbors over-length HBV
genome and secrets HBV virions (Sells et al., 1987), and Huh7 cell
line which is known to express miR-122 at low level. Quantitative
real time PCR analysis showed that, all the HepG2 or its derived
cell lines only express miR-122 at minimal level regardless of the
susceptibility for or existence of HBV (Fig. 4A). This observation
was in line with the previous report that expression of miR-122
was lost in liver cancer (Coulouarn et al., 2009). Nonetheless, as
miR-122 level in PTH was markedly increased upon HBV infection,
we were interested in whether HBV infection could induce miR-
122 expression in HepG2–NTCP cells. We inoculated HBV to the
stable cells at 100 m.g.e. and the level of miR-122 was examined
on different days post infection. HepG2–NTCP cells were readily
susceptible to HBV infection, secreted HBeAg peaked around day
6 post infection, while the miR-122 level was very low, and HBV
viral infection itself led to no or only modest variation of miR-122
level comparing to that of the viral infection of PTH from day 2 to
day 8 after infection (Fig. 4B).
In order to further understand the role of miR-122 in the HBV
infection process, we then tested if introducing mimic of miR-122
would enhance HBV infection on HepG2–NTCP cells. HepG2–NTCP
stable cells were transfected with 50 nM miR-122. Meanwhile, to
exclude the possibility that any residual miR-122 may affect the
viral infection course, we also transfected anti-miR-122 to HepG2–
NTCP cells. miR-122 or anti-miR-122 transfected HepG2–NTCP
stable cells were then inoculated with 100 m.g.e. of HBV. At
6 dpi, soluble viral antigen HBeAg (Fig. 4C, left panel), as well as
HBV 3.5 kb RNA (Fig. 4C right panel) were examined. Comparing to
the control groups, transfection of miR-122 or anti-miR-122 did
not alter HBV infection on HepG2–NTCP cells signiﬁcantly. Inde-
pendent transfection of miR-122 at a lower dose (20 nM) and
examining the infection with additional viral marker (HBsAg)
conﬁrmed the result (Fig. 4D). All these data demonstrated that
de novo HBV infection on susceptible cells including primary
hepatocytes (PTH) and HepG2–NTCP cells do not depend on the
expression of miR-122.
Fig. 3. Introducing miR-122 or anti-miR-122 did not alter HBV infection on PTH in
culture: (A) HepG2–hNTCP cells were transfected with the miR-122 ﬁreﬂy luciferase
reporter plasmid Fluc-slc 7A1 3′UTR (left) or a control reporter Fluc-control 3′ UTR
(right), along with an internal control plasmid expressing renilla luciferase (pRL-
TK). Indicated microRNA mimic or inhibitor, at a ﬁnal concentration of 50 nM, was
also transfected into the target cells, respectively. The activity of Fluc and Rluc was
determined 48 h after the transfection. The mean ratio of the luciferase activity was
presented. (B) ELISA detection of supernatant of PTH transfected with miRNA and
infected by HBV. Fresh PTHs were transfected with 50 nM synthesized miR-122 or
anti-miR-122 in 48-well plates, miR-cys and anti-miR-cy3 with scramble miRNA
sequence were used as controls. Additional controls included miR-let7c, anti-miR-
let7c and miRNA-NC with scramble sequence. The cells were challenged with HBV
at 100 m.g.e. for 48 h. Viral infection was evaluated by ELISA for secreted HBeAg at
different time point, data on 6 dpi was shown.
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Discussion
In this study, we ﬁrst established a high quality miRNA
database for the primary hepatocyte of tree shrew. The microRNA
database contains 168 unique mature miRNA sequences and laid
the foundation for future research on miRNA using northern
treeshrew, a valuable primate-like animal model in viral hepatitis.
We also proﬁled the miRNAs from PTH after HBV infection.
Although changes of the expression pattern of the microRNAs
may be limited by the relative low infection rate of HBV on the
target PTH cells, the data present an overall view of miRNA
expression in PTHs with or without HBV infection.
We further conducted experiments investigating the function-
ality of microRNAs for de novo infection of HBV. Although the
relative miR-122 level was increased upon HBV infection of PTH,
introducing either miR-122 mimic or miR-122 inhibitor did not
alter HBV infection in PTH. Furthermore, HepG2 cells complemen-
ted with the newly identiﬁed receptor NTCP (HepG2–NTCP) only
exhibited very limited expression of miR-122, introducing neither
miR-122 mimic nor miR-122 inhibitor had a detectable effect on
HBV infection in HepG2–NTCP cells. Therefore miR-122 is un-
likely involved in the bona ﬁde HBV infection. While several
previous studies indicated that miR-122 may indirectly decrease
HBV replication through cellular Heme oxygenase-1 (HO-1)
Fig. 4. HBV infection did not depend on the level of intracellular miR-122 on HepG2 cells complemented with NTCP: (A) The levels of miR-122 detected in cell lines of HepG2,
HepG2–NTCP, HepG2.2.15, Huh-7 and primary tupaia hepatocytes. miR-122 level in PTH and Huh7 was 1600-folds and 150-folds higher, respectively, than that of
HepG2; The level of miR-122 was extremely low in HepG2, HepG2–NTCP and HepG2.2.15. Copy number of the small RNA U6 was used as an inner control. (B) HepG2–NTCP
cells were infected with 100 m.g.e. HBV (Genotype D) in the presence of 4% PEG8000, the intracellular levels of miR-122 was examined by RT–qPCR on days 2, 4, 6 and 8 post
infection (dotted line), the relative miR-122 level was determined by using U6 as an inner control. The infection was assessed by viral antigen HBeAg ELISA on indicated days
post infection (solid line). (C) HepG2–NTCP cells were transfected with miR-122 or anti-miR-122 and indicated controls, 2 days later, the cells were inoculated with 100 m.g.
e. HBV (Genotype D) for 22 h in the presence of 4% PEG8000. Infection was evaluated at different time point, data of 6 dpi was shown. Left panel, ELISA result of HBeAg in the
cell supernatant, the detective limitation was shown as a dotted line; right panel was a real-time PCR result of HBV 3.5 kb RNA, which is presented as copy number of viral
RNA per nanogram total cellular RNA. (D) HepG2–NTCP cells were transfected with 20 nM or 50 nM miR-122 mimic and controls as indicated, the cells were inoculated with
100 m.g.e. HBV for 22 h. The viral infection was evaluated with ELISA on 6 dpi, HBsAg (left panel) and HBeAg (right panel) were detected from the supernatant of the cell.
The detective limitation was shown as a dotted line.
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(Qiu et al., 2010), or through inhibitory effect of p53 on HBV
transcription (Wang et al., 2012), or binding directly to the viral
target sequence (Chen et al., 2011). The reason for the discrepancy
is not clear, however, notably, the data supporting a role for miR-
122 in HBV replication were mainly obtained from transient
transfection experiments in liver cancer cell cultures, while our
study was performed on bona ﬁde infections of HBV on the
primary treeshrew hepatocytes or HepG2 cells complemented
with the HBV receptor (HepG2–NTCP). Transfection of HBV DNA
genome usually introduces large amount of viral genome into the
cells, which may obscure the effects of the factors critical for HBV
replication. While the de novo HBV infection could be limited by
the infection rate and the lack of robust viral spreading on the
target cells. More studies are thus warranted to further elucidate
the functionality of miR-122 during the entire HBV life cycle.
It has been reported that the level of miR-122 correlated with
HBV DNA and liver injury (Arataki et al., 2013), serum or plasma of
HBV patients contains large amount of miR-122 which is likely
associated with HBsAg subviral particles (Novellino et al., 2012).
However the level of intrahepatic miRNA-122 decreased in
patients with chronic HBV infection (Wang et al., 2012). An
unsolved question is how long the relative elevation of miR-122
level induced by HBV infection in hepatocytes may last. This is
difﬁcult to determine because cultured cells depreciate in vitro,
while data on the levels of miR-122 from longitudinal liver species
of HBV patients are currently unavailable. Of note, miR-122 may
function as a tumor suppressor in hepatocytes, mice with miR-122
deletion spontaneously developed liver tumor (Hsu et al., 2012;
Tsai et al., 2012; Wen and Friedman, 2012). It is reasonable to
speculate that, although HBV infection does not depend on the
expression of miR-122 per se, perturbation of the level of miR-122
by the viral infection may lead to cell injury with deleterious effect
on hepatocytes over time.
Materials and methods
Isolation and culturing primary hepatocyte from tree shrew
PTH cells were isolated as previously described (Yan et al.,
2012). Brieﬂy, tupaia (100–150 g) was anesthetized and the liver
was perfused with a two-step method (Walter et al., 1996). The
cells were resuspended in Williams E medium supplemented with
10% FBS, 5 μg/ml transferrin, 5 ng/ml sodium selenite, 2 mM L-
glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin.
1105 cells were plated on collagen-coated 48-well plates. 4 h
later, culture medium was changed to primary hepatocytes main-
tenance medium (PMM), which is, Williams E medium supple-
mented with 5 μg/ml transferrin, 10 ng/ml EGF, 3 μg/ml insulin,
2 mM L-glutamine, 18 μg/ml hydrocortisone, 40 ng/ml dexametha-
sone, 5 ng/ml sodium selenite, 2% DMSO, 100 U/ml penicillin, and
100 μg/ml streptomycin. Cells were cultured in 5% CO2 humidiﬁed
incubator at 37 1C, and the medium was refreshed every 2–3 days.
RNA deep sequencing of small RNAs from PTH
Fresh PTH were isolated and plated, the cells were inoculated
or not with HBV at 100 m.g.e. At 5 dpi, total RNA were extracted,
small RNAs with size of 18–28 nt were fractioned from 5–10 μg of
total RNA using 15% TBE urea polyacrylamide gel (TBU). The cDNA
libraries of small RNA were constructed by using the standard
Illumina libraries prep protocols. Brieﬂy, the 3′ RNA adapter was
ﬁrst ligated to the precipitated RNA using T4 RNA ligase 2, and
RNAs with a size between 36–50 nt were size-fractionated by TBU
from the ligated RNA. The 5′ RNA adapter was then ligated to the
RNA pool with T4 RNA ligase 1. The puriﬁed samples were reverse
transcribed, and ampliﬁed to generate the small RNA libraries.
Bioinformatic analysis of the miRNAs
Approximately 10–11 million total reads were obtained in each
sample, the data was processed to remove adapter sequences and
reads shorter than 18 nt. Then MiRDeep2 (https://www.mdc-ber
lin.de) was used to predict microRNA precursors and mature
sequences according to the miRDeep2 protocol, and a data set of
putative precursor and mature sequences was obtained based on
the newly completed genome sequence of treeshrew genome (Fan
et al., 2013). For further analysis, a very stringent selection process
was applied: ﬁrst, only conserved sequences presented in both
Mock and HBVþsamples were selected; second, for those mature
sequences with conserved seed sequence with published human
miRNAs at miRBase, we removed those without conserved pre-
cursors with their human counterparts, or, with reads less than 10,
or, with mirdeep score less than 3; third, for those mature
sequences without conserved seed sequences with published
human miRNAs in miRBase, we removed those with reads less
than 100 or with mirdeep score less than 10.
Construction of luciferase reporter system
Plasmids encoding ﬁreﬂy luciferase (Fluc) were used as repor-
ters. Fluc-slc7A1 3′UTR was used for examining the functionality
of miR-122 mimic. In FLuc-slc7A1 3′UTR plasmid, the Fluc gene
was ligated immediately after its stop codon with a 2501 bp
fragment originated from the 3′ UTR of human SLC7A1 (from
1870 bp to 4370 bp) which contains three miR-122 targeting
sites. The primers used for Fluc-slc7A1 3′UTR were 5′-TGAC-
GCACAGCCCCGCCCCC-3′ and 5′-GTCACTTGCACTGGTCCAAGTTC-
TACAATTTGGACTTTCCGCCCT-3′; Fluc-cn 3′ UTR was ﬁreﬂy lucifer-
ase followed by a 3′UTR from K-Ras (from 1129 bp to 1704 bp) and
served as a control. The primers used for Fluc-cn 3′ UTR were: 5′-
TAGCTCAACAAGATACAATCTCACTC-3′ and 5′-AAGGAAAAAA-
GCGGCCGCATTTACAGATTGTGCTGAGCTTGAC-3′. The genes were
cloned into pcDNA6.0 using restriction sites BamHI and NotI
Renilla luciferase (Rluc) expression plasmid (pRL-TK) was used as
an inner control. HepG2–hNTCP cells were transfected with 0.1 mg
plasmid of pRL-TK and 0.1 mg plasmid of Fluc slc7A1 3′UTR or Fluc-
cn 3′UTR, and mixed with 50 nM of mimics or inhibitors respec-
tively. Luciferase activity of Fluc and Rluc was determined 48 h
after transfection using a Centro LB96 microplate reader
(BERTHOL, Germany).
Quantiﬁcation of miR-122 and HBV 3.5 kb RNA with real time PCR
Total RNA were isolated with Trizol reagents, the miRNA ﬁrst
strand was synthesized using a commercial kit from Clontech
Laborataries (USA) according to the manufacture's speciﬁcations.
Q-PCR was performed with the 5′ primer: 5′-TGGAGTGTGA-
CAATGGTGTTTG-3′, 3′ primer was the mRQ 3′ primer provided
by the manufacturer. HBV2270F: 5′-GAGTGTGGATTCGCACTCC-3′
and HBV2392R: 5′-GAGGCGAG GGAGTTCTTCT-3′ were used for
HBV 3.5 kb RNA detection. Real time PCR was carried out on an ABI
Fast 7500 real-time system instrument. miR-122 level was
detected by relative quantiﬁcation with U6 small RNA as an inner
control. 3.5 kb RNA of HBV copies was quantiﬁed using GAPDH as
an inner control.
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Synthesis of microRNA mimics, inhibitors and microRNA transfection
MicroRNA mimics of miR-122, microRNA control mimic of miR-
cy3 and corresponding inhibitors of anti-miR-122, anti-miR-cy3
were purchased from Applied Biosystem (USA) and dissolved in
DEPC water. Other microRNAs including cel-miR-238, has-miR-let-
7c, anti-miR-let-7c and control miR-NC were purchased from Gene
Pharma (Shanghai, China). 50 nM microRNAs was transfected into
primary tupaia hepatocytes or HepG2–NTCP cells with Lipofecta-
mines RNAiMAX (Life Technologies, USA) following the manufac-
ture's protocol.
HBV infection on PTH and HepG2–NTCP cells
HBV infection on PTH and HepG2–NTCP cells were conducted
as reported previously (Zhong et al., 2013). Brieﬂy, freshly isolated
PTH was plated with a density of 0.8–1105/well (48-well plate)
and within 3 days, the cells were inoculated with 1107
genome equivalent copies of HBV for 20–24 h. HepG2–NTCP cells
were plated with a density of 1.2105/well (48-well plate) in
DMEM medium complemented with 10% fetal bovine serum,
2 mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomy-
cin for 4 h, then the mediumwas changed to PMM. 24 h later, cells
were inoculated with HBV at 100 m.g.e. in the presence of 4% PEG
8000. The cells were washed 3 times with WME and maintained
subsequently in PMM.
ELISA kits (Wantai, China) were used to detect the HBV
antigens from the supernatants of the cells at indicated days post
infection. HBV 3.5 kb RNA was detected by real time PCR with the
primer HBV2270F (5′-GAGTGTGGATTC GCACTCC-3′) and HBV23-
92R (5′-GAGGCGAGGGAGTTCTTCT-3′).
Statistical analysis
The HBV infection experiments upon transfection of microRNA
mimics or inhibitors were repeated at least two times and each
time with duplex samples. Student's t-test was used to detect the
differences between groups. A p-value less than 0.05 was con-
sidered signiﬁcant.
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